Review
Molecular Mechanisms of Melatonin-Mediated Cell Protection and Signaling in Health and Disease

Dalia M. Kopustinskiene 1 and Jurga Bernatoniene 1,2,*

1 Institute of Pharmaceutical Technologies, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania; DaliaMarija.Kopustinskiene@lsmuni.lt
2 Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania
* Correspondence: Jurga.Bernatoniene@lsmuni.lt

Abstract: Melatonin, an endogenously synthesized indolamine, is a powerful antioxidant exerting beneficial action in many pathological conditions. Melatonin protects from oxidative stress in ischemic/reperfusion injury, neurodegenerative diseases, and aging, decreases inflammation, modulates the immune system, inhibits proliferation, counteracts the Warburg effect, and promotes apoptosis in various cancer models. Melatonin stimulates antioxidant enzymes in the cells, protects mitochondrial membrane phospholipids, especially cardiolipin, from oxidation thus preserving integrity of the membranes, affects mitochondrial membrane potential, stimulates activity of respiratory chain enzymes, and decreases the opening of mitochondrial permeability transition pore and cytochrome c release. This review will focus on the molecular mechanisms of melatonin effects in the cells during normal and pathological conditions and possible melatonin clinical applications.

Keywords: melatonin; antioxidant; cardiolipin; mitochondria; cardioprotection; neuroprotection; tumor suppression

1. Introduction
The natural hormone melatonin (N-acetyl-5-methoxytryptamine) can be found in almost all species, such as fungi, plants, and animals [1]. The diet sources rich in melatonin include olives, rice, chamomile, green tea, coffee, tomatoes, and cereals [2,3]. Melatonin modulates many physiological functions, including sleep and circadian rhythm regulation, neuro- and cardioprotection, acting as powerful antioxidant and protecting from lipid peroxidation, inflammation, decreasing tumor growth, inducing apoptosis, and enhancing mitochondrial activity [1,4].

2. Melatonin Biosynthesis and Bioavailability
Melatonin is secreted primarily by the pineal gland, where it is synthesized from the amino acid tryptophan. Melatonin synthesis could also occur in other organs and cells, such as the bone marrow, brain, lens, skin, retina, and lymphocytes. Four essential enzymes are involved in melatonin synthesis: tryptophan-5-hydroxylase, 5-hydroxytryptophan decarboxylase, serotonin-N-acetyltransferase, and hydroxyindole-O-methyltransferase [5] (Figure 1). Around 30 µg/day of melatonin is secreted constantly in adult humans; however, in the evening, its synthesis increases reaching a maximum plasma peak in the middle of the dark period. As a neurohormone, melatonin is mainly involved in circadian rhythm control [1,6].

Melatonin is not retained in the pineal gland; it is secreted to the blood and transported to the liver, where it is rapidly metabolized [7]. First, cytochrome P450 monoxygenases A2 and 1A hydroxylate melatonin at the C6 position, then melatonin is converted to its sulfate derivative (6-sulfatoxymelatonin), and later excreted in the urine [7].
Melatonin is not retained in the pineal gland; it is secreted to the blood and transported to the liver, where it is rapidly metabolized [7]. First, cytochrome P450 monooxygenases A2 and 1A hydroxylate melatonin at the C6 position, then melatonin is converted to its sulfate derivative (6-sulfatoxymelatonin), and later excreted in the urine [7].

Melatonin is transported bound to the serum albumin in the blood, although it could be bound by hemoglobin as well [8,9]. It is capable of crossing the blood–brain barrier [10,11] and cellular membranes [12], and is found in high amounts in mitochondria within the cells [13,14].

The distribution half-life of melatonin is 0.5–5.6 min after intravenous administration [15,16]. After the administration of usual oral dosages (1–5 mg), the plasma concentration peak is reached after 60 min, and then rapidly decreases in a biphasic manner, with the corresponding half-life values of 2 and 20 min [15,16]. Basal melatonin concentrations are reached in 4–8 h. In healthy volunteers, an administration of 0.5 mg of melatonin resulted in a plasma melatonin peak varying between 2 and 395 nmol/L and an elimination half-life of 47 min, whereas bioavailability was around 33%, ranging from 10 to 56% [15,16]. The low melatonin bioavailability is due to excessive hepatic first pass metabolism [15–18].

The synthesis of melatonin decreases with age, often causing insomnia; the largest decline could be observed in the cases of Alzheimer’s disease, cardiovascular issues, and cancer [19]. Usually, melatonin is safe and not toxic; even at high doses only mild side effects, such as dizziness, headaches, nausea, and sleepiness, could be observed [20].

3. Receptor-Dependent Effects of Melatonin

Melatonin exerts its effects within the cells via interactions with receptors and with intracellular targets, such as transporters, ion binding proteins, enzymes, cytoskeletal components and mitochondria [9,14,21,22], due to its ability to cross freely membranes as well as penetrate the blood–brain barrier [12] (Figure 2).

Melatonin receptors are spread in the retina, brain, kidneys, gastrointestinal tract, skin, immune, endocrine, reproductive, and cardiovascular systems [5]. They modulate adenylyl cyclase (cAMP), guanylyl cyclase (cGMP) and phospholipase C (PLC) activities—and subsequently, calcium and potassium fluxes in the cell [23,24]. Melatonin receptors 1 (MT1) and 2 (MT2) are composed of 350 amino acids and 362 amino acids, respectively, and are 60% homologous proteins belonging to the class of G-protein-coupled receptors (GPCR) [23] with four intracellular and four extracellular domains and 7-transmembrane-
The MT1 receptor has an approximately three-fold higher affinity to melatonin than the MT2 receptor, and is thought to be responsible for the circadian effects of melatonin and modulation of the signal transduction in the reproductive system and regulation of peripheral vasoconstriction [26,27]. MT1 receptors are expressed in the retina, brain, cardiovascular system, immune system, skin, pancreas, kidney, liver, spleen, adrenal cortex, testes, ovary, placenta, and breast [26,27]. Most MT2 receptors are present in the retina, brain, immune system, adipose tissue, blood vessels, mammary glands, testes, kidney, and gastrointestinal tract [28]. Melatonin binding to MT1 and MT2 receptors results in the inhibition of the AC/cAMP/PKA/CREB signaling pathway [29], leading to the activation of calcium signaling by calmodulin kinases and PKC and regulation of hormone synthesis. Melatonin binding to the receptors could also activate the Rafs/MEK1/2/ERK1/2 signaling pathway [30,31], which is important for cell proliferation regulation [28]. The melatonin-modulated ERK–MAPK/JNK signaling pathway plays a major role in the oxidative stress [32]. Melatonin can activate the PI3K/Akt (PKB) signaling pathway [33,34] which is very important in cardioprotection [33]. Furthermore, melatonin can decrease tumor cell proliferation and viability by inhibiting the negative feedback from the downstream effector of the PI3K/Akt (PKB) signaling pathway—mammalian target of rapamycin complex 1 (mTOR) [35,36] and modulate apoptosis [37,38]—and inhibit the GC/cGMP/PKG pathway [39]. Melatonin receptor 3 (MT3) is found in animals and is a quinone reductase 2 (QR2) capable of neutralizing free radicals [40–42]. The melatonin effects on the nuclear retinoid Z receptor (ROR/RZR) protein family [9,43] play a role in melatonin immunomodulatory actions—T and B lymphocyte stimulation, inhibition of cytokine production, and suppression of nF-κB-dependent inflammation [43]. Thus, melatonin regulates many physiological functions via receptor-dependent signaling pathways.

The receptor-related melatonin effects comprise the indirect modulation of the activity of the enzymes involved in cellular protection against damage by reactive oxygen species (ROS) and reactive nitrogen species (RNS) [7,44,45]. Reduced glutathione (GSH) is one of the most important components of the first line of the antioxidant defense system in the cells capable of neutralizing ROS formed in a variety of redox reactions. The activities
of enzymes that improve intracellular levels of reduced GSH are maintained by melatonin [46]. Melatonin increases the activity of γ-glutamylcysteine synthase, which is the rate-limiting enzyme of the GSH synthesis pathway, thus maintaining the cellular levels of GSH [47,48]. Furthermore, melatonin can regulate GSH/GSSG (oxidized glutathione) balance by the stimulation of glutathione reductase (GR), responsible for GSSG reduction to GSH [46]. Melatonin can enhance the gene expression of antioxidant enzymes, comprising superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) [49,50], and increase catalase (CAT) activity [19]. Melatonin as an indirect antioxidant can also downregulate pro-oxidative and pro-inflammatory enzymes [51]. Melatonin suppresses the nitric oxide synthase, responsible for nitric oxide, and lipoxygenase, for superoxide anion generation [52]. Downregulation of lipoxygenase activity by melatonin protects the cells from the hydroperoxidation of polyunsaturated fatty acids [53]. Melatonin modulates endoplasmic reticulum stress responses [54], activity of sirtuins [55], and processes of mitophagy and autophagy [56,57]. Thus, melatonin is a powerful, multifaceted, natural antioxidant capable of preventing the overproduction of ROS and RNS, to protect the functions of many biological molecules—DNA, lipids, and proteins—from oxidative damage, and to suppress the development of severe degenerative disorders such as cardiologic and neurological diseases, diabetes, and cancer [49,50] (Figure 3).

Figure 3. Main biological effects of melatonin in the cell. ER—endoplasmic reticulum.

4. Receptor-Independent Effects of Melatonin

4.1. Direct Antioxidant Effects of Melatonin

Melatonin is a potent direct scavenger of free radicals, including singlet oxygen, hydroxyl, peroxyl radicals, hydrogen peroxide, nitric oxide and peroxynitrite. Melatonin effectively terminates the radical reaction chain without the formation of pro-oxidant metabolites [3,58] by donating one or more electrons to the free radicals [59]. It is very important that melatonin intermediates produced during free radical neutralization reactions—cyclic 3-hydroxymelatonin, N1-acetyl-N2-formyl-5-methoxykynuramine and N-acetyl-5-
methoxykynuramine—are also strong antioxidants [19]; thus, one melatonin molecule has the ability to scavenge up to 10 ROS compared to the traditional antioxidants that typically neutralize one ROS [19,51]. Melatonin can react with hydroxyl radical resulting in the formation of the indolyl radical cation, which has low reactivity and toxicity [60]. Melatonin also directly scavenges the alkoxyl radical, produced during the transition metal-catalyzed degradation of lipid peroxides, thus preventing further lipid peroxidation [61,62]. Melatonin also can act as metal chelator capable of reducing metal-induced toxicity [63].

4.2. Effects of Melatonin on Target Proteins

Melatonin can directly interact with various proteins within the cell, including enzymes, transporters, Ca$^{2+}$-binding proteins, and cytoskeleton components [9].

The zinc-dependent matrix metalloproteinases (MMPs) which are related to extracellular matrix remodeling and important in pathological processes such as tumor proliferation and the formation of metastasis, atherosclerosis, rheumatoid arthritis, and gastric ulcers, have been suggested to be one of the targets of melatonin [64]. Potent anti-ulcer action of melatonin is attributed to its possible binding to pepsin—a stomach protease responsible for breaking down the ingested proteins into peptides [65,66]. Melatonin-induced inhibition of phosphoprotein phosphatase 2A protects from the hyperphosphorylation of neuronal proteins, protecting neuronal cells and alleviating neurodegenerative diseases [67].

Melatonin is highly lipophilic and can therefore be distributed in the body by the means of passive diffusion [68]. Besides this mechanism, melatonin can be transported across the plasma membrane by the glucose transporter GLUT1 [37,69] and across the mitochondrial membranes by the oligopeptide transporters PEPT1/2 [70]. The melatonin binding site on GLUT1 overlaps with glucose binding [69], which might play a role in the counteraction of the Warburg effect in cancer cells by melatonin [71]. In the plasma, melatonin is bound by serum albumin [8,9].

Melatonin is a high affinity ligand of a Ca$^{2+}$-binding protein calmodulin, participating in many calcium signaling pathways [28,72]. The cytoskeletal effects of melatonin were suggested to be modulated by the Ca$^{2+}$-calmodulin complex, although at higher concentrations melatonin has been observed to bind tubulin [73–75], leading to the inhibition of microtubule formation. Melatonin via interactions with cytosolic protein networks can control cell motility, division, and organelle function, as well as in mitogen-activated protein kinase (MAPK)-related scaffold protein trafficking and signaling functions [28]. Melatonin can inhibit cytoskeleton reorganization; thus, suppressing cancer proliferation and restoring normal mitochondrial functions [76–78]. Melatonin has been shown to bind calreticulin—a Ca$^{2+}$-binding protein known for its chaperon action and responsible for the regulation of Ca$^{2+}$ homeostasis [79]. More than 15 melatonin target proteins have been proposed, capable of binding melatonin at concentrations ranging from subnanomolar to millimolar, and indicating the wide variety of processes that could be modulated by melatonin in the cells [9].

4.3. Effects of Melatonin on Epigenetic Regulation

MicroRNAs (miRNAs) have emerged as modulators of gene expression, capable of reaching various parts of organisms via their distribution in exosomes and ectosomes [80], and playing important roles in the development of many pathological conditions [80]. Melatonin has been shown to exert the protective activity by inducing changes in miRNA expression [80–83].

In a murine model, melatonin reduced the impairment of alcoholic liver disease by enhancing miRNA-497 expression [84], alleviated liver steatosis by modulating miRNA-23a expression [85], and reduced primary sclerosing cholangitis in a murine model of liver fibrosis by inhibiting miRNA-200b expression in cholangiocytes and stellate cells [86].

In Alzheimer’s disease models, melatonin partially suppressed neuroinflammation by reducing an increase in miRNA-124 and enhancing miRNA-132 [87]. Melatonin alleviated
neonatal brain inflammation in rats induced by bacterial lipopolysaccharide by restoring upregulated miRNA-34a and downregulated miRNA-146a and miR-126 activities [88].

In cancer models, melatonin suppressed miRNA-155 expression in several human glioma cell lines [89], inhibited angiogenesis modulated by miRNA-3195 and miRNA-374b expression in hypoxic PC-3 prostate cancer cells [90], inhibited the expression of 10 miRNA, and enhanced the expression of 12 miRNA in MCF-7 breast cancer cells [91]. Future directions for studies of the miRNA and melatonin interactions would be the clarification of whether melatonin could modulate the changes in the composition of exosomal and ectosomal miRNAs, thus affecting the progression of pathological conditions in the organism [80].

4.4. Effects of Melatonin on Mitochondrial Functions

Several studies indicate that, in subcellular compartments, melatonin may be differentially distributed. Cell nuclei and mitochondria, in particular, tend to contain higher levels of melatonin than other compartments, such as cytosol [70]. Mitochondria play a crucial role in metabolism, calcium homeostasis, apoptosis, and regulation of many physiological and pathological processes in the cells [92]. Mitochondria are essential organelles, responsible for cellular energy supply through oxidative phosphorylation as well as being the main site of ROS generation. ROS-induced impairment of mitochondrial and cellular functions can be controlled by either preventing the ROS formation or by scavenging them as soon as they are produced [93]. Mitochondria are the main sites for melatonin synthesis and metabolism [70,94], thus melatonin could be an ideal mitochondrial protector due to its close location to ROS production sites and its potent antioxidant properties (Figure 4).

Melatonin has been shown to improve mitochondrial functions, to stimulate the activity of the respiratory chain—mainly complexes I, III and IV [4,95–99]—and to increase mitochondrial ATP production in both normal and pathological conditions, although it did not change the activity of the ATP synthase [4,95–99]. The maintained ATP production at decreased oxygen flux and lower mitochondrial membrane potential is similar to the mild uncoupling, which is important for cardioprotection, neuroprotection, and the prevention of various pathological conditions due to decreased ROS generation [100,101]. Furthermore, the increased ATP production protects from the collapse of mitochondrial membrane potential and calcium overload and inhibits opening of the mitochondrial permeability transition pore (mPTP)—and subsequently, the cell death [102,103]. Peroxidation of mitochondrial

---

**Figure 4.** Main biological effects of melatonin in mitochondria. ETC—electron transport chain; ΔΨ—mitochondrial membrane potential; ROS—reactive oxygen species; mPTP—mitochondrial permeability transition pore; Cyt—cytochrome.
membrane phospholipids leads to mitochondrial dysfunction in aging and is the main cause of age-associated disorders [97,104–106]. The structure of membrane phospholipids is altered during peroxidation, resulting in the structural changes of the lipid bilayer, and altered membrane fluidity and permeability. Changed membrane properties influence the impairments in the mitochondrial electron transport and oxidative phosphorylation, inner membrane impermeability, decreased mitochondrial membrane potential and effects on mitochondrial Ca\(^{2+}\) homeostasis [107–109]. There is a high content of unsaturated fatty acids, such as linoleic acid, in cardiolipin molecules in the heart and liver, and arachidonic and docosahexaenoic acids in the cardiolipin molecules of brain tissue mitochondria, which are highly sensitive to ROS-induced damage [104,110]. Cardiolipin is present in the inner mitochondrial membrane, especially in intermembrane contact sites, near to the sites of ROS production, i.e., the respiratory chain complexes I and III [104,110]. The oxidation or decrease in cardiolipin in mitochondrial inner membrane is supposed to be responsible for age-related decline in mitochondrial functions [102,104]. Oxidized cardiolipin does not tightly bind cytochrome c (Cyt c) and it is released into the intermembrane space, then due to alterations in lipid bilayer, mPTP is formed [111], and Cyt c can be released to cytosol as a signal molecule for apoptosis processes. Melatonin has been shown to prevent cardiolipin peroxidation in mitochondria both under in vitro and in vivo conditions [102,106,112], thus preventing mPTP opening and cytochrome c release from mitochondria [113].

Melatonin also maintains mitochondrial bioenergetics and redox homeostasis via the regulation of mitochondrial dynamics [114]. Studies have revealed the importance of mitochondrial dynamics in inflammatory responses and the maintenance of immune synapse stability. Mitochondrial dynamics have been implicated to modulate the antigen-specific activation and immune responses [115]. Mitochondria have been shown to move towards the immune synapse, driven by cell polarization and integrin adhesion [115–117], as well as the fission factor dynamin-related protein 1 (Drp1) regulating mitochondrial redistribution in response to T cell receptor assembly [116].

Melatonin has been shown to exert multiple anticancer effects related to mitochondrial function regulation. A fundamental protective mechanism for reducing pathologies may be the ability of melatonin to alter metabolism in cancer cells as well as other metabolically compromised cells due to the suppression of aerobic glycolysis and activation of oxidative phosphorylation [71,118,119]. Besides inhibiting aerobic glycolysis, melatonin also down-regulates survival signaling and metastasis formation [38]. Melatonin modulates the activity of pyruvate kinase complex and suppresses the pyruvate dehydrogenase kinase, which is considered to be a potential therapeutic target in cancer [120]. The restoration of the mitochondrial network by melatonin increases apoptosis, thus reducing cell growth in lung, breast, and colon cancers [121–123].

Thus, melatonin, via its direct ROS/RNS scavenging at its production site—mitochondria—indirect activation of antioxidant defense system, and preservation of the integrity of mitochondrial membranes by protecting them from cardiolipin loss and its peroxidation, has a crucial role in maintaining normal physiological functions of mitochondria and energy turnover in the cells. Melatonin is highly present in mitochondrial membranes; therefore, future studies of the effects of melatonin on the functions of mitochondria in various tissues and organs under normal and pathological conditions as well as investigations of mitochondria-targeted melatonin preparations could help to elucidate the detailed mechanisms of the protective actions of melatonin and its role in alleviating many pathological conditions.

5. Beneficial Effects of Melatonin in Pathological Conditions
5.1. Effects of Melatonin in Neurodegenerative Disorders

Age-related conditions that share mitochondrial dysfunction, oxidative/nitrosative stress, and apoptosis in multiple parts of the brain are neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease [124,125]. Reduced melatonin levels are found in the blood and cerebrospinal fluid of Alzheimer’s patients, even in the early onset
of the disease [126]. In a rat model of sporadic Alzheimer’s disease, melatonin attenuated memory decline, amyloid-β accumulation, and neurodegeneration [127]. In a Parkinson’s disease model, melatonin restored electron transport chain complex I and complex IV activities, and downregulated mitochondrial inducible nitric oxide synthase by decreasing nitric oxide radicals in mitochondria from substantia nigra and striatum [128]. Decreased local melatonin synthesis in neuronal and immune cells, as well as in the glia and gut, might be important to the etiology and management of Parkinson’s disease [129]. Melatonin has been shown to be neuroprotective in various models of neurodegenerative diseases (for reviews see refs [56,57,130–132]). Clinical trials have also been performed to investigate the role of melatonin supplementation on the alleviation of clinical symptoms during Alzheimer’s disease [130]. In studies evaluating sleep efficiency, contradictory results were obtained—melatonin did not show beneficial effects in several studies [133–135], probably due to the stability of the assessment method used [130]. A slight neuroprotective effect of melatonin was observed when subjective criteria (Pittsburg Sleep Quality Index) [136] or actigraphy [137] were used to evaluate the melatonin effects. Nevertheless, the majority of clinical investigations support the beneficial effects of melatonin on cognitive impairment and sleep disorders [130].

5.2. Cardioprotective Effects of Melatonin

Melatonin is a cardioprotective agent, reducing the cardiac damage and changes in cellular physiology during ischemia/reperfusion injury due to actions at mitochondrial level [99,112,138,139]. Melatonin treatment of an ischemic/reperfused rat heart significantly decreased the level of lipid peroxidation, restored decreased mitochondrial respiration rate in State 3, as well as complex I and complex III activities in isolated rat heart mitochondria [22,112]. Furthermore, melatonin treatment resulted in a decrease in H2O2 generation, protected from cardiolipin loss, and its peroxidation thus preserving the physiological functions of mitochondrial membranes, the ETC activity, and preventing mPTP opening and cytochrome c loss [112,113,139,140]. Melatonin pretreatment attenuates IR-induced mitochondrial oxidative damage via the activation of the JAK2/STAT3 signaling pathway [141]. The STAT3 is a transcription factor of the manganese superoxide dismutase gene, which can increase manganese superoxide dismutase antioxidant activity, thus improving mitochondrial antioxidant defense [142]. Moreover, melatonin can also up-regulate mitochondrial STAT3 through the SAFE signal transduction pathway to reduce myocardial ischemia/reperfusion injury [143]. During ischemia/reperfusion in diabetic rats, melatonin protected mitochondrial functions by alleviating mitochondrial oxidative stress and stimulating mitochondrial biogenesis via up-regulation of the AMPK–PGC-1α–silent information regulator 3 (SIRT3) axis [144].

5.3. Effects of Melatonin in Diabetes, Obesity and Metabolic Diseases

Metabolic diseases—cardiovascular diseases, diabetes, obesity, and metabolic syndromes—are caused by the altered normal physiological processes in the organism [145–147]. Melatonin receptors MT1 and MT2 are expressed in islets of Langerhans and they can modulate α-cell-dependent glucagon secretion and β-cell-dependent insulin secretion [148]. Altered signaling of melatonin receptors, especially MT2 activation, could lead to the development of type-2 diabetes mellitus [148]. Melatonin concentration changes are important for the blood glucose-regulating function of the islets [145,148]. The inverse relationship between insulin and melatonin secretion was reported in the studies on diabetic rat models [148]. Furthermore, melatonin was able to inhibit glucose-induced insulin release in rodents [145,149]. Elevated insulin and leptin levels could suppress the increase in melatonin synthesis at night [150]. Additionally, the aging-related increase in insulin resistance could be prevented by melatonin as well [150]. Melatonin modulated body weight regulation and restored the insulin sensitivity in obese young rats on a high-fat diet [151,152]. Melatonin also decreased abdominal fat and plasma leptin levels in middle-aged rats [153,154]. Thus, melatonin could prevent body weight gain without
affecting the food intake [145,154–156], due to elevated energy expenditure, mainly in brown adipose tissue [156,157] or a stimulation of physical activity or basal metabolic rate [145]. Hypo-lipidemic effects of melatonin were reported in rodents [152,158] and humans [159,160]. In peri- and post-menopausal women, melatonin up-regulated their high-density-lipoprotein cholesterol levels, but not the concentrations of total cholesterol [161]. Melatonin also decreased low-density-lipoprotein cholesterol and triglyceride levels simultaneously, increasing high-density-lipoprotein cholesterol levels in diabetic patients [159,160,162]. Further investigations of melatonin’s influence on mitochondrial functions in obesity or diabetes are expected to detail its mechanisms of alleviation of metabolic diseases [145–147].

5.4. Effects of Melatonin in Skeletal Muscle Disorders

The decreased level of melatonin in postmenopausal women was reported in sarcopenia [163,164]. Melatonin supplementation protected mitochondria from aging-caused impairment in cardiac and diaphragm muscles in the model of accelerated aging in mice [165]. Melatonin reduced the inflammation and increased glycolytic potential in skeletal muscles during sarcopenia [166]. Furthermore, melatonin protected from the development of sarcopenia in aged rodent models [167,168]. Melatonin protected from ischemic damage in rat cremaster and gracilis muscles during ischemia/reperfusion [169,170], and enhanced cell regeneration in rat muscle injury models [171,172]. In rodent fibromyalgia models, melatonin protected from ROS damage and restored mitochondrial dynamics parameters in the gastrocnemius muscle [164,173,174]. Melatonin, due to its antioxidant activity, was also effective in alleviating Duchenne muscular dystrophy in rodents and humans [175,176].

5.5. Immunomodulatory Effects of Melatonin

Melatonin exerts a potent immunomodulatory activity in vivo and in vitro [177–179]. Melatonin membrane receptors are present in T and B lymphocytes [69]. Melatonin promotes T cell differentiation from the type 1 helper T cells and regulates cytokine gene expression [180,181]. Furthermore, melatonin can enhance cytokine production in human peripheral blood mononuclear cells via its action on nuclear receptors [182].

Melatonin is a pleiotropic immunomodulatory agent, activating inflammation at an early phase via up-regulation of pro-inflammatory phospholipase A2, lipooxygenase, and cytokines (IL-1 and tumor necrosis factor alpha (TNF-α)) [183–185]. The anti-inflammatory action of melatonin is related to the suppression of Th1 function and activation of type 2 helper T lymphocytes which produce interleukin (IL)-4 [69].

Melatonin decreases NF-kB binding to DNA, probably by preventing its translocation to the nucleus, thus down-regulating cytokine production [186,187]. Melatonin suppresses chronic inflammation, inhibiting the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase, as well as protein lipase A2, lipooxygenase and cytokine activities due to its antioxidant properties [188]. This activity is similar to that of flavonoids, acting as antioxidants under physiological and as pro-oxidants under pathological conditions.

5.6. Effects of Melatonin in Gastrointestinal Tract

Alterations in gut microbiota and increased gut permeability are implicated in the etiology, course, and treatment of many neurodegenerative diseases [129]. Moreover, the exposure to stress induces changes in the brain–gut interactions, leading to the development of gastrointestinal disorders [189]. Melatonin is present in significant amounts in the gastrointestinal tract, directly affecting its tissues and indirectly modulating the brain–gut axis [129,190,191]. Melatonin protects from the increase in the ROS-induced lipid peroxidation and up-regulates key anti-oxidizing enzymes such as superoxide dismutase [129]. Melatonin restores gastric and pancreatic functions and is implicated in the healing of gastric ulcers, thus beneficially affecting the brain–gut axis [190–193].
5.7. The Role of Melatonin in the Treatment of the Protozoan Parasitic Infections

Melatonin has been shown to be beneficial in bacterial, viral, and parasitic infections due to its potent antioxidant immunomodulatory effects and direct effects on mitochondrial functions [194]. Melatonin suppressed the development of Plasmodium parasites in malaria due to regulation of cAMP–PKA and IP3–Ca^{2+} signaling pathways [195–198]. In Chagas’ disease [199], toxoplasmosis [200] and African trypanosomiasis [201], melatonin stimulated the host’s immune response against the parasite, up-regulating the production of inflammatory mediators. Melatonin inhibited leishmaniasis parasite replication via direct effects on mitochondrial functions—activating the efflux of Ca^{2+} from mitochondria, increasing the level of mitochondrial nitrates, and suppressing the superoxide dismutase activity [202]. Serum melatonin levels were elevated in giardiasis patients, implicating that the increased melatonin concentrations could modulated phagocytic activity [203]. In amoebiasis, melatonin decreased the amoebic lesions and enhanced the leukophagocytosis [204].

Melatonin, such as many other antiparasitic drugs—ivermectin [205–209], doxycycline [210–212], metronidazole [213], mefloquine [214], and hydroxychloroquine [215,216]—has been suggested as a possible adjuvant agent in the treatment of coronavirus disease 2019 (COVID-19) infection [217–221]. Due to its anti-inflammatory, antioxidant and potent mitoprotective properties, melatonin might be beneficial in the preservation of mitochondrial functions and neuro- and cardioprotection during infections, whereas clarification of its mechanism of action as antiparasitic agent would be an interesting topic for further research.

6. Conclusions and Future Perspectives

Melatonin, an endogenous hormone synthetized from tryptophan in the pineal gland mainly during the dark period of the day, regulates the circadian rhythm, can cross cellular membranes and the blood–brain barrier, and is finally driven to mitochondria, where it protects from ROS directly at their generation site—the mitochondrial electron transport chain. Melatonin is most powerful natural antioxidant, alleviating cellular injury during many pathological conditions, such as ischemia/reperfusion, neurodegenerative diseases, aging, and exerting anti-proliferative, anti-inflammatory, and anti-cancer effects. Melatonin acts via receptor-dependent and independent pathways, modulating various signal transduction steps and supporting the healthy state of mitochondria, preventing the cellular energy supply from impairment. Melatonin is well tolerated as a supplement even at high doses (1–5 mg, [15–18]), and could serve as a potential adjuvant remedy in many degenerative and infectious diseases and for the sleep regulation. The novel pharmacological melatonin formulations such as prolonged-release tablets or melatonin liposomes, niosomes, or nanoparticles for alternative administration routes—e.g., intranasal or transdermal delivery—could be developed to overcome the problems related to the short therapeutic window of melatonin caused by the poor oral absorption and low bioavailability due to the high first-pass metabolism.

Author Contributions: Conceptualization, D.M.K. and J.B.; literature review and resources, D.M.K. and J.B.; writing—original draft preparation, D.M.K. and J.B.; writing—review and editing, D.M.K. and J.B.; visualization, D.M.K. and J.B.; supervision, J.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors wish to thank the Pharmaceutical and Health Technology Open Access Center for support of this study.
**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Hardeland, R.; Cardinali, D.P.; Srinivasan, V.; Spence, D.W.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin—A pleiotropic, orchestrating regulator molecule. *Prog. Neurobiol. 2011*, *93*, 350–384. [CrossRef] [PubMed]

2. Bonomini, F.; Borsani, E.; Favero, G.; Rodella, L.F.; Rezzi, R. Dietary Melatonin Supplementation Could Be a Promising Preventing/Therapeutic Approach for a Variety of Liver Diseases. *Nutrients 2018*, *10*, 1135. [CrossRef] [PubMed]

3. Fan, J.; Xie, Y.; Zhang, Z.; Chen, L. Melatonin: A Multifunctional Factor in Plants. *Int. J. Mol. Sci. 2018*, *19*, 1528. [CrossRef] [PubMed]

4. Acuña-Castroviejo, D.; López, L.C.; Escames, G.; López, A.; García, J.A.; Reiter, R.J. Melatonin-mitochondria interplay in health and disease. *Curr. Top. Med. Chem. 2011*, *11*, 221–240. [CrossRef] [PubMed]

5. Dubocovich, M.L.; Markowska, M. Functional MT1 and MT2 melatonin receptors in mammals. *Endocrine 2005*, *27*, 101–110. [CrossRef]

6. Carpentieri, A.; Díaz de Barboza, G.; Areco, V.; Peralta López, M.; Tolosa de Talamoni, N. New perspectives in melatonin uses. *Pharmacol. Res. 2012*, *65*, 437–444. [CrossRef]

7. Acuña-Castroviejo, D.; Escames, G.; Venegas, C.; Díaz-Casado, M.E.; Lima-Cabello, E.; López, L.C.; Rosales-Corral, S.; Tan, D.X.; Reiter, R.J. Extrapancreatic melatonin: Sources, regulation, and potential functions. *Cell. Mol. Life Sci. CMLS 2014*, *71*, 2997–3025. [CrossRef]

8. Cardinali, D.P.; Lynch, H.J.; Wurtman, R.J. Binding of melatonin to human and rat plasma proteins. *Endocrinology 1972*, *91*, 1213–1218. [CrossRef]

9. Liu, L.; Labani, N.; Cecon, E.; Jockers, R. Melatonin Target Proteins: Too Many or Not Enough? *Front. Endocrinol. 2019*, *10*, 791. [CrossRef]

10. Castagnola, E.; Robbins, E.M.; Woeppe1, K.M.; McGuier, M.; Golabchi, A.; Taylor, I.M.; Michael, A.C.; Cui, X.T. Real-Time Fast Scan Cyclic Voltammetry Detection and Quantification of Exogenously Administered Melatonin in Mice Brain. *Front. Bioeng. Biotechnol. 2020*, *8*, 602216. [CrossRef]

11. Pardridge, W.M.; Mietus, L.J. Transport of albumin-bound melatonin through the blood-brain barrier. *J. Neurochem. 1980*, *34*, 1761–1763. [CrossRef] [PubMed]

12. Legros, C.; Chesneau, D.; Boutin, J.A.; Barc, C.; Malpax, B. Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions. *J. Neuroendocrinol. 2014*, *26*, 151–163. [CrossRef] [PubMed]

13. Reiter, R.J.; Tan, D.X.; Mayo, J.C.; Sainz, R.M.; Leon, J.; Czarnocki, Z. Melatonin as an antioxidant: Biochemical mechanisms and pathophysiological implications in humans. *Acta Biochim. Pol. 2003*, *50*, 1129–1146. [CrossRef]

14. Acuña-Castroviejo, D.; Martín, M.; Macías, M.; Escames, G.; León, J.; Khaldy, H.; Reiter, R.J. Melatonin, mitochondria, and cellular bioenergetics. *J. Pineal Res. 2001*, *30*, 65–74. [CrossRef] [PubMed]

15. Iguchi, H.; Kato, K.I.; Ibayashi, H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. *J. Clin. Endocrinol. Metab. 1982*, *54*, 1025–1027. [CrossRef]

16. Di, W.L.; Kadva, A.; Johnston, A.; Silman, R. Variable bioavailability of oral melatonin. *N. Engl. J. Med. 1997*, *336*, 1028–1029. [CrossRef]

17. Waldhauser, F.; Saletu, B.; Trinchard-Lugan, I. Sleep laboratory investigations on hypnotic properties of melatonin. *Psychopharmacology 1990*, *100*, 222–226. [CrossRef]

18. Clauser, B.; Brun, J.; Chazot, G. The basic physiology and pathophysiology of melatonin. *Sleep Med. Rev. 2005*, *9*, 11–24. [CrossRef]

19. Reiter, R.J.; Mayo, J.C.; Tan, D.X.; Sainz, R.M.; Alatorre-Jimenez, M.; Qin, L. Melatonin as an antioxidant: Under promises but over deliveries. *J. Pineal Res. 2016*, *61*, 253–278. [CrossRef]

20. Al-Omary, F.A. Melatonin: Comprehensive profile. *Profiles Drug Subst. Excip. Relat. Methodol. 2013*, *38*, 159–226. [CrossRef]

21. López, A.; García, J.A.; Escames, G.; Venegas, C.; Ortiz, F.; López, L.C.; Acuña-Castroviejo, D. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. *J. Pineal Res. 2009*, *46*, 188–198. [CrossRef] [PubMed]

22. Leon, J.; Acuña-Castroviejo, D.; Sainz, R.M.; Mayo, J.C.; Tan, D.X.; Reiter, R.J. Melatonin and mitochondrial function. *Life Sci. 2004*, *75*, 765–790. [CrossRef] [PubMed]

23. Stau&th, B.; Johansson, L.C.; Cherezov, V. Structural insights into melatonin receptors. *FEBS J. 2020*, *287*, 1496–1510. [CrossRef] [PubMed]

24. Liu, J.; Clough, S.J.; Hutchinson, A.J.; Adamah-Biassi, E.B.; Popovska-Gorevski, M.; Dubocovich, M.L. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. *Annu. Rev. Pharmacol. Toxicol. 2016*, *56*, 361–383. [CrossRef] [PubMed]

25. Dubocovich, M.L.; Rivera-Bermudez, M.A.; Gerdin, M.J.; Masana, M.I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. *Front. Biosci. A J. Virtual Libr. 2003*, *8*, d1093–d1108. [CrossRef]

26. Pala, D.; Lodola, A.; Bedini, A.; Spadoni, G.; Rivara, S. Homology models of melatonin receptors: Challenges and recent advances. *Int. J. Mol. Sci. 2013*, *14*, 8093–8121. [CrossRef]

27. Jockers, R.; Delagrange, P.; Dubocovich, M.L.; Markus, R.P.; Renault, N.; Tosini, G.; Cecon, E.; Zlotos, D.P. Update on melatonin receptors: IUPHAR Review 20. *Br. J. Pharmacol. 2016*, *173*, 2702–2725. [CrossRef]
28. Luchetti, F.; Canonico, B.; Betti, M.; Arcangeletti, M.; Pilolli, F.; Piroddi, M.; Canesi, L.; Papa, S.; Galli, F. Melatonin signaling and cell protection function. *FASEB J.* 2010, 24, 3603–3624. [CrossRef]

29. Godson, C.; Reppert, S.M. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. *Endocrinology* 1997, 138, 397–404. [CrossRef]

30. Zhu, H.Q.; Cheng, X.W.; Xiao, L.L.; Jiang, Z.K.; Zhou, Q.; Gui, S.Y.; Wei, W.; Wang, Y. Melatonin prevents oxidized low-density lipoprotein-induced increase of myosin light chain kinase activation and expression in HUVEC through ERK/MAPK signal transduction. *J. Pineal Res.* 2008, 45, 328–334. [CrossRef]

31. Luchetti, F.; Betti, M.; Canonico, B.; Arcangeletti, M.; Ferri, P.; Galli, F.; Papa, S. ERK MAPK activation mediates the antiapoptotic signaling of melatonin in UVB-stressed U937 cells. *Free Radic. Biol. Med.* 2009, 46, 339–351. [CrossRef] [PubMed]

32. Kimball, S.R.; Abbas, A.; Jefferson, L.S. Melatonin represses oxidative stress-induced activation of the MAP kinase and mTOR signaling pathways in H4IE hepatoma cells through inhibition of Ras. *J. Pineal Res.* 2008, 44, 379–386. [CrossRef] [PubMed]

33. Luo, G.P.; Jian, Z.; Ma, R.Y.; Cao, Z.Z.; Zhu, Y.; Zhu, Y.; Tang, F.Q.; Xiao, Y.B. Melatonin alleviates hypoxia-induced cardiac apoptosis through PI3K/Akt pathway. *Int. J. Clin. Exp. Pathol.* 2018, 11, 5840–5849. [PubMed]

34. Beker, M.C.; Caglayan, B.; Caglayan, A.B.; Kelestemur, T.; Yalcin, E.; Caglayan, A.; Kilic, U.; Baykal, A.T.; Reiter, R.J.; Kilic, E. Interaction of melatonin and Bmal1 in the regulation of PI3K/AKT pathway components and cellular survival. *Sci. Rep.* 2019, 9, 19082. [CrossRef]

35. Kim, H.S.; Kim, T.J.; Yoo, Y.M. Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells. *PLoS ONE* 2014, 9, e92627. [CrossRef]

36. Shen, Y.Q.; Guerra-Libredo, A.; Fernandez-Gil, B.I.; Florida, J.; Garcia-López, S.; Martinez-Ruiz, L.; Mendivil-Perez, M.; Soto-Mercado, V.; Acuña-Castroviejo, D.; Ortega-Arellano, H.; et al. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation. *J. Pineal Res.* 2018, 64. [CrossRef]

37. Zawilska, J.B.; Skene, D.J.; Arendt, J. Physiology and pharmacology of melatonin in relation to biological rhythms. *Pharmacol. Rep.* 2009, 61, 383–410. [CrossRef]

38. Mortezaee, K.; Najafi, M.; Farhood, B.; Ahmadi, A.; Potes, Y.; Shabeeb, D.; Ahmadi, A.; Potes, Y.; Shabeeb, D.; Musa, A.E. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. *Life Sci.* 2019, 228, 228–241. [CrossRef]

39. Spangle, J.M.; Roberts, T.M.; Zhao, J.J. The emerging role of PI3K/IKK-mediated epigenetic regulation in cancer. *Biochim. Biophys. Acta Rev. Cancer* 2017, 1868, 123–131. [CrossRef]

40. Černýsiov, V.; Mauricas, M.; Girkontaitė, I. Melatonin inhibits granulocyte adherence to ICAM via MT3/QR2 and MT2 receptors. *Int. Immunol.* 2015, 27, 599–608. [CrossRef]

41. Nosjean, O.; Nicolas, J.P.; Klupsch, F.; Delagrange, P.; Canet, E.; Boutin, J.A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. *Tissue distribution of MT3/QR2.* *Biochem. Pharmacol.* 2001, 61, 1369–1379. [CrossRef]

42. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchere, J.L.; Delagrange, P.; Canet, E.; Boutin, J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. *J. Biol. Chem.* 2000, 275, 31311–31317. [CrossRef] [PubMed]

43. Smirnov, A.N. Nuclear melatonin receptors. *Biochem. Biokhimiya* 2001, 66, 19–26. [CrossRef] [PubMed]

44. Acuña-Castroviejo, D.; Escames, G.; López, L.C.; Hitsot, A.B.; León, J. Melatonin and nitric oxide: Two required antagonists for mitochondrial homeostasis. *Endocrine* 2005, 27, 159–168. [CrossRef]

45. Gilad, E.; Cuzzocrea, S.; Zingarelli, B.; Salzman, A.L.; Szabó, C. Melatonin is a scavenger of peroxynitrite. *Life Sci.* 1997, 60, PL169–PL174. [CrossRef]

46. Pablos, M.I.; Agapito, M.T.; Gutierrez, R.; Recio, J.M.; Reiter, R.J.; Barlow-Walden, L.; Acuña-Castroviejo, D.; Menendez-Pelaez, A. Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. *J. Pineal Res.* 1995, 19, 111–115. [CrossRef]

47. Escames, G.; López, L.C.; Tapia, V.; Utrilla, P.; Reiter, R.J.; Hitsot, A.B.; León, J.; Rodríguez, M.I.; Acuña-Castroviejo, D. Melatonin counteracts inductible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. *J. Pineal Res.* 2006, 40, 70–78. [CrossRef]

48. Uratu, Y.; Honma, S.; Goto, T.; Sodoroki, S.; Iida, T.; Cho, S.; Honma, K.; Kondo, T. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. *Free Radic. Biol. Med.* 1999, 27, 838–847. [CrossRef]

49. Reiter, R.J.; Tan, D.X.; Osuna, C.; Gitto, E. Actions of melatonin in the reduction of oxidative stress. A review. *J. Biomed. Sci.* 2000, 7, 444–458. [CrossRef]

50. Bonnefont-Rousselot, D.; Collin, F. Melatonin: Action as antioxidant and potential applications in human disease and aging. *Toxicology* 2010, 278, 55–67. [CrossRef]

51. Zhang, H.M.; Zhang, Y. Melatonin: A well-documented antioxidant with conditional pro-oxidant actions. *J. Pineal Res.* 2014, 57, 131–146. [CrossRef] [PubMed]

52. Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Pilar Terron, M.; Flores, L.J.; Koppisepi, S. Medical implications of melatonin: Receptor-mediated and receptor-independent actions. *Adv. Med. Sci.* 2007, 52, 11–28. [PubMed]

53. Blokhina, O.; Virolainen, E.; Fagerstedt, K.V. Antioxidants, oxidative damage and oxygen deprivation stress: A review. *Ann. Bot.* 2003, 91, 179–194. [CrossRef] [PubMed]
54. Fernández, A.; Ordóñez, R.; Reiter, R.J.; González-Gallego, J.; Mauriz, J.L. Melatonin and endoplasmic reticulum stress: Relation to autophagy and apoptosis. J. Pineal Res. 2015, 59, 292–307. [CrossRef] [PubMed]
55. Mayo, J.C.; Sainz, R.M.; González Menéndez, P.; Cepas, V.; Tan, D.X.; Reiter, R.J. Melatonin and sirtuins: A “not-so unexpected” relationship. J. Pineal Res. 2017, 62. [CrossRef]
56. Luo, F.; Sandhu, A.F.; Rungratanananich, W.; Williams, G.E.; Akbar, M.; Zhou, S.; Song, B.J.; Wang, X. Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. Int. J. Mol. Sci. 2020, 21, 7174. [CrossRef]
57. Stacchiotti, A.; Corsetti, G. Natural Compounds and Autophagy: Allies Against Neurodegeneration. Front. Cell Dev. Biol. 2020, 8, 555409. [CrossRef]
58. Mortezaei, K.; Potes, Y.; Mirtavoos-Mahyari, H.; Motvevaseli, E.; Shabeb, D.; Musa, A.E.; Najafi, M.; Farhood, B. Boosting immune system against cancer by melatonin: A mechanistic viewpoint. Life Sci. 2019, 238, 116960. [CrossRef]
59. Reiter, R.J.; Guerrero, J.M.; García, J.J.; Acuña-Castroviejo, D. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann. N. Y. Acad. Sci. 1998, 854, 410–424. [CrossRef]
60. Galano, A.; Tan, D.X.; Reiter, R.J. Melatonin as a natural ally against oxidative stress: A physicochemical examination. J. Pineal Res. 2011, 51, 1–16. [CrossRef]
61. Reiter, R.J.; Tan, D.X.; Galano, A. Melatonin reduces lipid peroxidation and membrane viscosity. Front. Physiol. 2014, 5, 377. [CrossRef] [PubMed]
62. Garcia, J.J.; López-Pingarrón, L.; Almeida-Souza, P.; Tres, A.; Escudero, P.; García-Gil, F.A.; Tan, D.X.; Reiter, R.J.; Ramírez, J.M.; Bernal-Pérez, M. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: A review. J. Pineal Res. 2014, 56, 225–237. [CrossRef] [PubMed]
63. Romero, A.; Ramos, E.; de Los Rios, C.; Egea, J.; Del Pino, J.; Reiter, R.J. A review of metal-catalyzed molecular damage: Protection by melatonin. J. Pineal Res. 2014, 56, 343–370. [CrossRef] [PubMed]
64. Swarnakar, S.; Paul, S.; Singh, L.P.; Reiter, R.J. Matrix metalloproteinases in health and disease: Regulation by melatonin. J. Pineal Res. 2011, 50, 8–20. [CrossRef] [PubMed]
65. Bubenik, G.A. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol. Signals Recept. 2001, 10, 350–366. [CrossRef]
66. Majka, J.; Wierdak, M.; Brzozowska, I.; Magierowski, M.; Szlachcic, A.; Wojcik, D.; Kwiecien, S.; Magierowska, K.; Zagajewski, J.; Brzozowski, T. Melatonin in Prevention of the Sequence from Reflux Esophagitis to Barrett’s Esophagus and Esophageal Adenocarcinoma: Experimental and Clinical Perspectives. J. Pineal Res. 2011, 50, 292–307. [CrossRef] [PubMed]
67. Gong, Y.H.; Hua, N.; Zang, X.; Huang, T.; He, L. Melatonin ameliorates Aβ(1-42)-induced Alzheimer’s cognitive deficits in mouse model. J. Pharm. Pharmacol. 2018, 70, 70–80. [CrossRef]
68. Yu, H.; Dickson, E.J.; Jung, S.R.; Koh, D.S.; Hille, B. High membrane permeability of melatonin. J. Gen. Physiol. 2016, 147, 63–76. [CrossRef]
69. Ren, W.; Liu, G.; Chen, S.; Yin, J.; Wang, J.; Tan, B.; Wu, G.; Bazer, F.W.; Peng, Y.; Li, T.; et al. Melatonin signaling in T cells: Functions and applications. J. Pineal Res. 2017, 62. [CrossRef]
70. Mayo, J.C.; Sainz, R.M.; González-Menéndez, P.; Hevia, D.; Cernuda-Cernuda, R. Melatonin transport into mitochondria. Cell. Mol. Life Sci. 2017, 74, 3927–3940. [CrossRef] [PubMed]
71. Reiter, R.J.; Sharma, R.; Ma, Q.; Rorsales-Corral, S.; de Almeida Chuffa, L.G. Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: A mechanistic hypothesis. Cell. Mol. Life Sci. 2020, 77, 2527–2542. [CrossRef]
72. Benítez-King, G.; Antón-Tay, F. Calmodulin mediates melatonin cytoskeletal effects. Experientia 1993, 49, 635–641. [CrossRef] [PubMed]
73. Huerto-Delgadillo, L.; Antón-Tay, F.; Benítez-King, G. Effects of melatonin on microtubule assembly depend on hormone concentration: Role of melatonin as a calmodulin antagonist. J. Pineal Res. 1994, 17, 55–62. [CrossRef] [PubMed]
74. Freire, F.; Cardinali, D.P. Effects of melatonin treatment and environmental lighting on the ultrastructural appearance, melatonin synthesis, norepinephrine turnover and microtubule protein content of the rat pineal gland. J. Neural Transm. 1975, 37, 237–257. [CrossRef]
75. Jarzynka, M.J.; Passey, D.K.; Johnson, D.A.; Konduru, N.V.; Fitz, N.F.; Radio, N.M.; Rasenick, M.; Benloucif, S.; Melan, M.A.; Witt-Endery, P.A. Microtubules modulate the melatonin receptors involved in phase-shifting circadian activity rhythms: In vitro and in vivo evidence. J. Pineal Res. 2014, 46, 169–171. [CrossRef] [PubMed]
76. Yoon, Y.M.; Go, G.; Yun, C.W.; Lim, J.H.; Lee, J.H.; Lee, S.H. Melatonin Suppresses Renal Cortical Fibrosis by Inhibiting Cytoskeleton Reorganization and Mitochondrial Dysfunction through Regulation of miR-456. Int. J. Mol. Sci. 2020, 21, 5323. [CrossRef]
77. Álvarez-Artieme, A.; Cernuda-Cernuda, R.; Francisco Artieme, N.; Cepas, V.; González-Menendez, P.; Fernández-Vega, S.; Quiros-González, I.; Sainz, R.M.; Mayo, J.C. Melatonin-Induced Cytoskeleton Reorganization Leads to Inhibition of Melanoma Cancer Cell Proliferation. Int. J. Mol. Sci. 2020, 21, 548. [CrossRef]
78. Su, S.C.; Hsieh, M.J.; Yang, W.E.; Chung, W.H.; Reiter, R.J.; Yang, S.F. Cancer metastasis: Mechanisms of inhibition by melatonin. J. Pineal Res. 2017, 62. [CrossRef]
79. Macías, M.; Escames, G.; Leon, J.; Coto, A.; Sibih, Y.; Osuna, A.; Acuña-Castroviejo, D. Calreticulin-melatonin. An unexpected relationship. Eur. J. Biochem. 2003, 270, 832–840. [CrossRef] [PubMed]
80. Hardeled, R. Aging, Melatonin, and the Pro- and Anti-Inflammatory Networks. Int. J. Mol. Sci. 2019, 20, 1223. [CrossRef]
81. Korkmaz, A.; Rosales-Corral, S.; Reiter, R.J. Gene regulation by melatonin linked to epigenetic phenomena. *Gene* 2012, 503, 1–11. [CrossRef] [PubMed]

82. Hardeland, R. Melatonin, noncoding RNAs, messenger RNA stability and epigenetics—Evidence, hints, gaps and perspectives. *Int. J. Mol. Sci.* 2014, 15, 18221–18252. [CrossRef] [PubMed]

83. Hardeland, R. Melatonin and the pathologies of weakened or dysregulated circadian oscillators. *J. Pineal Res.* 2017, 62. [CrossRef] [PubMed]

84. Kim, Y.D.; Hwang, S.L.; Lee, E.J.; Kim, H.M.; Chung, M.J.; Elfadl, A.K.; Lee, S.E.; Nedumaran, B.; Harris, R.A.; Jeong, K.S. Melatonin ameliorates alcohol-induced bile acid synthesis by enhancing miR-497 expression. *J. Pineal Res.* 2017, 62. [CrossRef] [PubMed]

85. Kim, S.J.; Kang, H.S.; Lee, J.H.; Park, J.H.; Jung, C.H.; Bae, J.H.; Oh, B.C.; Song, D.K.; Baek, W.K.; Im, S.S. Melatonin ameliorates ER stress-mediated hepatic steatosis through miR-23a in the liver. *Biochem. Biophys. Res. Commun.* 2015, 458, 462–469. [CrossRef]

86. Wu, N.; Meng, F.; Zhou, T.; Han, Y.; Kennedy, L.; Venter, J.; Francis, H.; DeMorrow, S.; Onori, P.; Invernizzi, P.; et al. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation. *FASEB J.* 2017, 31, 4305–4324. [CrossRef]

87. Hardeland, R.; Cardinali, D.P.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin and brain inflammaging. *Prog. Neurobiol.* 2015, 127–128, 46–63. [CrossRef]

88. Wang, X.; Wang, Z.H.; Wu, Y.Y.; Tang, H.; Tan, L.; Wang, X.; Gao, X.Y.; Xiong, Y.S.; Liu, D.; Wang, J.Z.; et al. Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPAC1/miR-124/Er11 pathway. *Mol. Neurobiol.* 2013, 47, 373–381. [CrossRef]

89. Gu, J.; Lu, Z.; Ji, C.; Chen, Y.; Liu, Y.; Lei, Z.; Wang, L.; Zhang, H.T.; Li, X. Melatonin inhibits proliferation and invasion via repression of miR-155 in glioma cells. *Biomed. Pharmacother.* 2017, 93, 969–975. [CrossRef]

90. Sohn, E.J.; Won, G.; Lee, J.; Lee, S.; Kim, S.H. Ureprotection of miRNA3195 and miRNA374b Mediates the Anti-Angiogenic Properties of Melatonin in Hypoxic PC-3 Prostate Cancer Cells. *J. Cancer* 2015, 6, 19–28. [CrossRef]

91. Lee, S.E.; Kim, S.J.; Youn, J.P.; Hwang, S.Y.; Park, C.S.; Park, Y.S. MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. *J. Pineal Res.* 2011, 51, 345–352. [CrossRef] [PubMed]

92. Abate, M.; Festa, A.; Falco, M.; Lombardi, A.; Luce, A.; Grimaldi, A.; Zappavigna, S.; Spolvergano, P.; Iraee, C.; Caraglia, M.; et al. Mitochondria as playmakers of apoptosis, autophagy and senescence. *Semin. Cell Dev. Biol.* 2020, 98, 139–153. [CrossRef] [PubMed]

93. Dröse, S.; Brandt, U.; Wittig, I. Mitochondrial respiratory chain complexes as sources and targets of thiol-based redox-regulation. *Biochim. Biophys. Acta* 2014, 1844, 1344–1354. [CrossRef] [PubMed]

94. Reiter, R.J.; Rosales-Corral, S.; Tan, D.X.; Jou, M.J.; Galano, A.; Xu, B. Melatonin as a mitochondria-targeted antioxidant: One of evolution’s best ideas. *Cell. Mol. Life Sci.* 2017, 74, 3863–3881. [CrossRef] [PubMed]

95. Acuña-Castroviejo, D.; Escames, G.; Carazo, A.; León, J.; Khaldy, H.; Reiter, R.J. Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. *Curr. Top. Med. Chem.* 2002, 2, 133–151. [CrossRef]

96. Acuña-Castroviejo, D.; Escames, G.; León, J.; Carazo, A.; Khaldy, H. Mitochondrial regulation by melatonin and its metabolites. *Adv. Exp. Med. Biol.* 2003, 527, 549–557. [CrossRef]

97. Paradis, G.; Paradies, V.; Ruggiero, F.M.; Petrosillo, G. Protective role of melatonin in mitochondrial dysfunction and related disorders. *Arch. Toxicol.* 2015, 89, 923–939. [CrossRef]

98. Paradis, G.; Paradies, V.; Ruggiero, F.M.; Petrosillo, G. Mitochondrial bioenergetics decay in aging: Beneficial effect of melatonin. *Cell. Mol. Life Sci.* 2017, 74, 3897–3911. [CrossRef] [PubMed]

99. Paradis, G.; Di Venosa, N.; Pistolese, M.; Casanova, G.; Tiravanti, E.; Colantuono, G.; Federici, A.; Paradies, G.; Ruggiero, F.M. Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: Role of cardiolipin. *FASEB J.* 2006, 20, 269–276. [CrossRef]

100. Starkov, A.A. “Mild” uncoupling of mitochondria. *Biosci. Rep.* 1997, 17, 273–279. [CrossRef]

101. Skulachev, V.P. Uncoupling: New approaches to an old problem of bioenergetics. *Biochim. Biophys. Acta* 1998, 1363, 100–124. [CrossRef]

102. Petrosillo, G.; Moro, N.; Ruggiero, F.M.; Paradis, G. Melatonin inhibits cardiolipin peroxidation in mitochondria and prevents the mitochondrial permeability transition and cytochrome c release. *Free Radic. Biol. Med.* 2009, 47, 969–974. [CrossRef] [PubMed]

103. Petrosillo, G.; Ruggiero, F.M.; Paradis, G. Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. *FASEB J.* 2003, 17, 2202–2208. [CrossRef]

104. Paradis, G.; Paradies, V.; Ruggiero, F.M.; Petrosillo, G. Cardiolipin and mitochondrial function in health and disease. *Antioxid. Redox Signal.* 2014, 20, 1925–1953. [CrossRef] [PubMed]

105. Paradis, G.; Petrosillo, G.; Paradies, V.; Ruggiero, F.M. Oxidative stress, mitochondrial bioenergetics, and cardiolipin in aging. *Free Radic. Biol. Med.* 2010, 48, 1286–1295. [CrossRef]

106. Paradis, G.; Ruggiero, F.M.; Petrosillo, G.; Quagliariello, E. Peroxidative damage to cardiac mitochondria: Cytochrome oxidase and cardiolipin alterations. *FEBS Lett.* 1998, 424, 155–158. [CrossRef]

107. Paradis, G.; Paradies, V.; Ruggiero, F.M.; Petrosillo, G. Role of Cardiolipin in Mitochondrial Function and Dynamics in Health and Disease: Molecular and Pharmacological Aspects. *Cells* 2019, 8, 728. [CrossRef]
Paradies, G.; Petrosillo, G.; Paradies, V.; Reiter, R.J.; Ruggiero, F.M. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. *J. Pineal Res.* 2010, 48, 297–310. [CrossRef]

Petrosillo, G.; Casanova, G.; Matera, M.; Ruggiero, F.M.; Paradies, G. Interaction of peroxidized cardiolipin with rat-heart mitochondrial membranes: Induction of permeability transition and cytochrome c release. *FEBS Lett.* 2006, 580, 6311–6316. [CrossRef]

Paradies, G.; Paradies, V.; De Benedictis, V.; Ruggiero, F.M.; Petrosillo, G. Functional role of cardiolipin in mitochondrial bioenergetics. *Biochim. Biophys. Acta* 2014, 1837, 408–417. [CrossRef]

Kagan, V.E.; Chu, C.T.; Tyrurina, Y.Y.; Cheikhi, A.; Bayir, H. Cardiolipin asymmetry, oxidation and signaling. *Chem. Phys. Lipids* 2014, 179, 64–69. [CrossRef] [PubMed]

Petrosillo, G.; Colantuono, G.; Moro, N.; Ruggiero, F.M.; Tiraventi, E.; Di Venosa, N.; Fiore, T.; Paradies, G. Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. *Am. J. Physiol. Heart Circ. Physiol.* 2009, 297, H1487–H1493. [CrossRef] [PubMed]

Paradies, G.; Petrosillo, G.; Paradies, V.; Ruggiero, F.M. Role of cardiolipin peroxidation and Ca²⁺ in mitochondrial dysfunction and disease. *Cell Calcium* 2009, 45, 643–650. [CrossRef] [PubMed]

Paramayong, A.; Govitrapong, P.; Chetsawang, B. Melatonin attenuates the mitochondrial translocation of mitochondrial fission proteins and Bax, cytosolic calcium overload and cell death in methamphetamine-induced toxicity in neuroblastoma SH-SY5Y cells. *Mitochondrion* 2015, 24, 1–8. [CrossRef] [PubMed]

Martín-Cófreces, N.B.; Baixauli, F.; Sánchez-Madrid, F. Immune synapse: Conductor of orchestrated organelle movement. *Trends Cell Biol.* 2014, 24, 61–72. [CrossRef] [PubMed]

Quintana, A.; Schwindling, C.; Wenning, A.S.; Becherer, U.; Rettig, J.; Schwarz, E.C.; Hoth, M. T cell activation requires mitochondrial translocation to the immunological synapse. *Proc. Natl. Acad. Sci. USA* 2007, 104, 14418–14423. [CrossRef]

Baixauli, F.; Martín-Cófreces, N.B.; Morlino, G.; Carrasco, Y.R.; Calabia-Linares, C.; Veiga, E.; Serrador, J.M.; Sánchez-Madrid, F. The mitochondrial fission factor dynamin-related protein 1 modules T-cell receptor signalling at the immune synapse. *EMBO J.* 2011, 30, 1238–1250. [CrossRef]

Proietti, S.; Cucina, A.; Minini, M.; Bizzarri, M. Melatonin, mitochondria, and the cancer cell. *Cell. Mol. Life Sci.* 2017, 74, 4015–4025. [CrossRef]

Reiter, R.J.; Sharma, R.; Ma, Q. Switching diseased cells from cytosolic aerobic glycolysis to mitochondrial oxidative phosphorylation: A metabolic rhythm regulated by melatonin? *J. Pineal Res.* 2020, e12677. [CrossRef]

Ghareghani, M.; Scavo, L.; Jand, Y.; Farhadi, N.; Sadeghi, H.; Ghanbari, A.; Mondello, S.; Arnoult, D.; Gharaghani, S.; Zibara, K. Melatonin Therapy Modulates Cerebral Metabolism and Enhances Remyelination by Increasing PDK4 in a Mouse Model of Multiple Sclerosis. *Front. Pharmacol.* 2019, 10, 147. [CrossRef]

Rehman, J.; Zhang, H.J.; Toth, P.T.; Zhang, Y.; Marsboom, G.; Hong, Z.; Salgia, R.; Husain, A.N.; Wietholt, C.; Archer, S.L. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. *FASEB J.* 2012, 26, 2175–2186. [CrossRef] [PubMed]

Hagenbuchner, J.; Kuznetsov, A.V.; Obexer, P.; Ausserlechner, M.J. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. *Oncogene* 2013, 32, 4748–4757. [CrossRef]

Inoue-Yamauchi, A.; Oda, H. Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells. *Biochem. Biophys. Res. Commun.* 2012, 421, 81–85. [CrossRef] [PubMed]

Hardeland, R. Recent Findings in Melatonin Research and Their Relevance to the CNS. *Cent. Nerv. Syst. Agents Med. Chem.* 2018, 12, 108–114. [CrossRef] [PubMed]

Balmik, A.A.; Chinnathambi, S. Multi-Faceted Role of Melatonin in Neuroprotection and Amelioration of Tau Aggregates in Alzheimer’s Disease. *J. Alzheimer’s Dis.* 2018, 62, 1481–1493. [CrossRef] [PubMed]

Liu, R.Y.; Zhou, J.N.; van Heerikhuize, J.; Hofman, M.A.; Swaab, D.F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. *J. Clin. Endocrinol. Metab.* 1999, 84, 323–327. [CrossRef]

Rudnitskaya, E.A.; Muraleva, N.A.; Maksimova, K.Y.; Kiseleva, E.; Kolosova, N.G.; Stefanova, N.A. Melatonin Attenuates Memory Impairment, Amyloid-β Accumulation, and Neurodegeneration in a Rat Model of Sporadic Alzheimer’s Disease. *J. Alzheimer’s Dis.* 2015, 47, 103–116. [CrossRef]

Tapias, V.; Escames, G.; López, L.C.; López, A.; Camacho, E.; Carrión, M.D.; Entrena, A.; Gallo, M.A.; Espinosa, A.; Acuña-Castroviejo, D. Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthesis induction in parkinsonian mice. *J. Neurosci. Res.* 2009, 87, 3002–3010. [CrossRef]

Anderson, G.; Seo, M.; Berk, M.; Carvalho, A.F.; Maes, M. Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways. *Curr. Pharm. Des.* 2016, 22, 6142–6151. [CrossRef]

Chen, D.; Zhang, T.; Lee, T.H. Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. *BioMolecules* 2020, 10, 1158. [CrossRef]

Lee, J.G.; Woo, Y.S.; Park, S.W.; Seog, D.H.; Seo, M.K.; Bahk, W.M. The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease. *Brain Sci.* 2019, 9, 285. [CrossRef] [PubMed]
132. Shukla, M.; Govitrapong, P.; Boontem, P.; Reiter, R.J.; Satayavivad, J. Mechanisms of Melatonin in Alleviating Alzheimer’s Disease. *Curr. Neuropharmacol.* **2017**, *15*, 1010–1031. [CrossRef] [PubMed]

133. Alves, G.S.; Carvalho, A.F.; de Amorim de Carvalho, L.; Sudo, F.K.; Siqueira-Neto, J.I.; Oertel-Knochel, V.; Jurcoane, A.; Knochel, C.; Boecker, H.; Laks, J.; et al. Neuroimaging Findings of Behavioral Disturbances in Alzheimer’s Disease: A Systematic Review. *Curr. Alzheimer Res.* **2017**, *14*, 61–75. [CrossRef]

134. Serfaty, M.; Kennell-Webb, S.; Warner, J.; Blizard, R.; Raven, P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. *Int. J. Geriatr. Psychiatry* **2002**, *17*, 1120–1127. [CrossRef][PubMed]

135. Singer, C.; Trachtenberg, R.E.; Kaye, J.; Schafer, K.; Gamsn, A.; Grundman, M.; Thomas, R.; Thal, L.J. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. *Sleep* **2003**, *26*, 893–901. [CrossRef]

136. Wade, A.G.; Farmer, M.; Harari, G.; Fund, N.; Laudon, M.; Nir, T.; Frydman-Marom, A.; Zisapel, N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: A 6-month, randomized, placebo-controlled, multicenter trial. *Clin. Interv. Aging* **2014**, *9*, 947–961. [CrossRef]

137. Asayama, K.; Yamadera, H.; Ito, T.; Suzuki, H.; Kudo, Y.; Endo, S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. *J. Nippon Med. School* **2003**, *70*, 334–341. [CrossRef]

138. Aslan, G.; Göl, H.F.; Tektemur, A.; Sahna, E. Ischemic postconditioning reduced myocardial ischemia-reperfusion injury: The roles of melatonin and uncoupling protein 3. *Anatol. J. Cardiol.* **2020**, *23*, 19–27. [CrossRef]

139. Ma, Z.; Xin, Z.; Di, W.; Yan, X.; Li, X.; Reiter, R.J.; Yang, Y. Melatonin and mitochondrial function during ischemia/reperfusion injury. *Cell. Mol. Life Sci.* **2017**, *74*, 3989–3998. [CrossRef]

140. Leon, J.; Acuña-Castroviejo, D.; Escames, G.; Tan, D.X.; Reiter, R.J. Melatonin mitigates mitochondrial malfunction. *J. Pineal Res.* **2005**, *38*, 8–19. [CrossRef]

141. Yang, B.; Zang, L.E.; Cui, J.W.; Zhang, M.Y.; Ma, X.; Wei, L.L. Melatonin Plays a Protective Role by Regulating miR-26a-5p-NRSF and JAK2/STAT3 Pathway to Improve Autophagy, Inflammation and Oxidative Stress of Cerebral Ischemia-Reperfusion Injury. *Drug Des. Dev. Ther.* **2020**, *14*, 3177–3188. [CrossRef][PubMed]

142. Zhen, G.; Liang, W.; Jia, H.; Zheng, X. Melatonin relieves sepsis-induced myocardial injury via regulating JAK2/STAT3 signaling pathway. *Minerva Med.* **2020**, *111*, 1–7. [CrossRef][PubMed]

143. Lochner, A.; Huisman, B.; Ndudirabandi, F. Cardioprotective effect of melatonin against ischaemia/reperfusion damage. *Front. Biosci.* **2013**, *18*, 305–315. [CrossRef]

144. Yu, L.; Gong, B.; Duan, W.; Fan, C.; Zhang, J.; Li, Z.; Xue, X.; Xu, Y.; Meng, D.; Li, B.; et al. Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: Role of AMPK-PGC-1α-SIRT3 signaling. *Sci. Rep.* **2017**, *7*, 41337. [CrossRef]

145. Navarro-Alarcón, M.; Ruiz-Ojeda, F.J.; Blanca-Herrera, R.M.; MM, A.S.; Acuña-Castroviejo, D.; Fernández-Vázquez, G.; Agil, A. Melatonin and metabolic regulation: A review. *Food Funct.* **2014**, *5*, 2806–2832. [CrossRef][PubMed]

146. Karamitri, A.; Jockers, R. Melatonin in type 2 diabetes mellitus and obesity. *Nat. Rev. Endocrinol.* **2019**, *15*, 105–125. [CrossRef][PubMed]

147. Cardinale, D.P.; Vigo, D.E. Melatonin, mitochondria, and the metabolic syndrome. *Cell. Mol. Life Sci.* **2017**, *74*, 3941–3954. [CrossRef][PubMed]

148. Peschke, E.; Bähr, I.; Mühlbauer, E. Melatonin and pancreatic islets: Interrelationships between melatonin, insulin and glucagon. *Int. J. Mol. Sci.* **2013**, *14*, 6981–7015. [CrossRef]

149. Peschke, E.; Wolgast, S.; Bazwinsky, I.; Pönicke, K.; Mühlbauer, E. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. *J. Pineal Res.* **2008**, *45*, 439–448. [CrossRef]

150. Rasmussen, D.D.; Mitton, D.R.; Larsen, S.A.; Yellon, S.M. Aging-dependent changes in the effect of daily melatonin supplementation on rat metabolic and behavioral responses. *J. Pineal Res.* **2001**, *31*, 89–94. [CrossRef]

151. Prunet-Marcussus, B.; Desbaeille, M.; Bros, A.; Louché, K.; Delagrange, P.; Renard, P.; Castella, L.; Pénaud, L. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. *Endocrinology* **2003**, *144*, 5347–5352. [CrossRef][PubMed]

152. Agil, A.; Rosado, I.; Ruiz, R.; Figueroa, A.; Zen, N.; Fernández-Vázquez, G. Melatonin improves glucose homoeostasis in young Zucker diabetic fatty rats. *J. Pineal Res.* **2012**, *52*, 203–210. [CrossRef]

153. Rasmussen, D.D.; Boldt, B.M.; Wilkinson, C.W.; Yellon, S.M.; Matsumoto, A.M. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. *Endocrinology* **1999**, *140*, 1009–1012. [CrossRef][PubMed]

154. Wolden-Hanson, T.; Mitton, D.R.; McCants, R.L.; Yellon, S.M.; Wilkinson, C.W.; Matsumoto, A.M.; Rasmussen, D.D. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. *Endocrinology* **2000**, *141*, 487–497. [CrossRef]

155. Raskind, M.A.; Burke, B.L.; Crites, N.J.; Tapp, A.M.; Rasmussen, D.D. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. *Neuropsychopharmacology* **2007**, *32*, 284–288. [CrossRef]

156. Tan, D.X.; Manchester, L.C.; Fuentes-Broto, L.; Paredes, S.D.; Reiter, R.J. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: Relation to human obesity. *Obes. Rev.* **2011**, *12*, 167–188. [CrossRef]

157. Cannon, B.; Nedergaard, J. Brown adipose tissue: Function and physiological significance. *Physiol. Rev.* **2004**, *84*, 277–359. [CrossRef]
183. Acuña-Castroviejo, D.; Rahim, I.; Acuña-Fernández, C.; Fernández-Ortiz, M.; Solera-Marín, J.; Sayed, R.K.A.; Díaz-Casado, M.E.; Rusanova, I.; López, L.C.; Escames, G. Melatonin, clock genes and mitochondria in sepsis. Cell. Mol. Life Sci. 2017, 74, 3965–3987. [CrossRef] [PubMed]
184. Mauriz, J.L.; Collado, P.S.; Veneroso, C.; Reiter, R.J.; González-Gallego, J. A review of the molecular aspects of melatonin’s anti-inflammatory actions: Recent insights and new perspectives. J. Pineal Res. 2015, 54, 1–14. [CrossRef] [PubMed]
185. Reiter, R.J.; Calvo, J.R.; Karbownik, M.; Qi, W.; Tan, D.X. Melatonin and its relation to the immune system and inflammation. Annu. N. Y. Acad. Sci. 2000, 917, 376–386. [CrossRef]
186. Chuang, J.I.; Mohan, N.; Meltz, M.L.; Reiter, R.J. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol. Int. 1996, 20, 687–692. [CrossRef] [PubMed]
187. Mohan, N.; Sadeghi, K.; Reiter, R.J.; Meltz, M.L. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa-B. Biochem. Mol. Biol. Int. 1995, 37, 1063–1070.
188. Deng, W.G.; Tang, S.T.; Tseng, H.P.; Wu, K.K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006, 108, 518–524. [CrossRef]
189. Konturek, P.C.; Brzozowski, T.; Konturek, S.J. Stress and the gut: Pathophysiology, clinical consequences, diagnostic approach and treatment options. J. Physiol. Pharmacol. 2011, 62, 591–599.
190. Konturek, S.J.; Konturek, P.C.; Konturek, S.J. Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers. J. Physiol. Pharmacol. 2006, 57 (Suppl. 5), 51–66.
191. Jaworek, J.; Nawrot-Porabka, K.; Leja-Szpak, A.; Konturek, S.J. Brain-gut axis in the modulation of pancreatic enzyme secretion. J. Physiol. Pharmacol. 2010, 61, 523–531.
192. Sgambato, D.; Capuano, A.; Sullo, M.G.; Miranda, A.; Federico, A.; Romano, M. Gut-Brain Axis in Gastric Mucosal Damage and Protection. Curr. Neuropharmacol. 2016, 14, 959–966. [CrossRef] [PubMed]
193. Jaworek, J.; Brzozowski, T.; Konturek, S.J. Melatonin as an organoprotector in the stomach and the pancreas. J. Pineal Res. 2005, 38, 73–83. [CrossRef] [PubMed]
194. Daryani, A.; Montazemi, M.; Paghhe, A.S.; Sharif, M.; Sarvi, S.; Hosseinzadeh, A.; Reiter, R.J.; Joghataei, M.T.; Ghaznavi, H.; et al. The potential use of melatonin to treat protozoan parasitic infections: A review. Biomed. Pharmacother. 2018, 97, 948–957. [CrossRef] [PubMed]
195. Scarpelli, P.H.; Tessarin-Almeida, G.; Viçoso, K.L.; Lima, W.R.; Borges-Pereira, L.; Meissner, K.A.; Wrenger, C.; Raffaello, A.; Daryani, A.; Montazeri, M.; Pagheh, A.S.; Sharif, M.; Sarvi, S.; Hosseinzadeh, A.; Joghataei, M.T.; Ghaznavi, H.; et al. The potential use of melatonin to treat protozoan parasitic infections: A review. Biomed. Pharmacother. 2018, 97, 948–957. [CrossRef] [PubMed]
196. Scarpelli, P.H.; Tessarin-Almeida, G.; Viçoso, K.L.; Lima, W.R.; Borges-Pereira, L.; Meissner, K.A.; Wrenger, C.; Raffaello, A.; Daryani, A.; Montazeri, M.; Pagheh, A.S.; Sharif, M.; Sarvi, S.; Hosseinzadeh, A.; Joghataei, M.T.; Ghaznavi, H.; et al. The potential use of melatonin to treat protozoan parasitic infections: A review. Biomed. Pharmacother. 2018, 97, 948–957. [CrossRef] [PubMed]
197. Ghaznavi, H.; et al. The potential use of melatonin to treat protozoan parasitic infections: A review. Biomed. Pharmacother. 2018, 97, 948–957. [CrossRef] [PubMed]
198. Srinivasan, V.; Zakaria, R.; Mohamed, M.; Saleh, R.M. Effects of melatonin derivatives on human malaria parasite Plasmodium falciparum. Recent Pat. Endoc. Metab. Immune Drug Discov. 2014, 8, 102–108. [CrossRef]
199. Srinivasan, V.; Mohamed, M.; Zakaria, R.; Ahmad, A.H. Malaria, anti malarial drugs and the role of melatonin. Infect. Disord. Drug Targets 2012, 12, 371–379. [CrossRef]
200. Santello, F.H.; Frare, E.O.; Caetano, L.C.; AlonsoToldo, M.P.; do Prado, J.C., Jr. Melatonin enhances pro-inflammatory cytokine levels and protects against Chaegas disease. J. Pineal Res. 2008, 45, 79–85. [CrossRef]
201. Machado, N.I.; Dos Santos, T.A.T.; de Souza, W.; DaMatta, R.A.; Seabra, S.H. Treatment with melatonin induces a reduction of Toxoplasma gondii development in LLC-MK2 cells. Parasitol. Res. 2020, 119, 2703–2711. [CrossRef]
202. Kristensson, K.; Claustrat, B.; Mhlanga, J.D.; Meller, M. African trypanosomiasis in the rat alters melatonin secretion and melatonin receptor binding in the suprachiasmatic nucleus. Brain Res. Bull. 1998, 47, 265–269. [CrossRef]
203. Elmahallawy, E.K.; Jiménez-Aranda, A.; Martínez, A.S.; Rodríguez-Granger, J.; Navarro-Alarcón, M.; Gutiérrez-Fernández, J.; Agil, A. Activity of melatonin against Leishmania infantum promastigotes by mitochondrial dependent pathway. Chem. Biol. Interact. 2014, 220, 84–93. [CrossRef] [PubMed]
204. Pereira, Q.L.C.; Hara, C.C.P.; Fernandes, R.T.S.; Fagundes, D.L.G.; França-Botelho, A.D.C.; Gomes, M.A.; França, E.L.; Honório-França, A.C. Human colostrum action against Giardia lamblia infection influenced by hormones and advanced maternal age. Parasitol. Res. 2018, 117, 1783–1791. [CrossRef] [PubMed]
205. França-Botelho, A.C.; França, J.L.; Oliveira, F.M.; França, E.L.; Honório-França, A.C.; Caliari, M.V.; Gomes, M.A. Melatonin reduces the severity of experimental amoebiosis. Parasites Vectors 2011, 4, 62. [CrossRef]
206. Sen Gupta, P.S.; Rana, M.K. Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19. ACS Pharmacol. Transl. Sci. 2020, 3, 1037–1038. [CrossRef]
207. Khan, M.S.I.; Khan, M.S.I.; Debnath, C.R.; Nath, P.N.; Mahtab, M.A.; Nabeka, H.; Matsuda, S.; Akbar, S.M.F. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Arch. Bronconeumol. 2020, 56, 828–830. [CrossRef]
208. Hellwig, M.D.; Maia, A. A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin. Int. J. Antimicrob. Agents 2020, 106248. [CrossRef]
209. Mittal, N.; Mittal, R. Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19? Med. Hypotheses 2020, 110364. [CrossRef]
210. Padhy, B.M.; Mohanty, R.R.; Das, S.; Meher, B.R. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J. Pharm. Pharm. Sci. 2020, 23, 462–469. [CrossRef]
210. Yates, P.A.; Newman, S.A.; Oshry, L.J.; Glassman, R.H.; Leone, A.M.; Reichel, E. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther. Adv. Respir. Dis. 2020, 14. [CrossRef]

211. Milionis, H.; Kostikas, K. Is it prime time to consider a clinical trial of doxycycline for the management of COVID-19? Postgrad. Med. J. 2020. [CrossRef] [PubMed]

212. Gendrot, M.; Andreani, J.; Jardot, P.; Hutter, S.; Delandre, O.; Boxberger, M.; Mosnier, J.; Le Bideau, M.; Duflot, I.; Fonta, I.; et al. In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. Molecules 2020, 25, 5064. [CrossRef] [PubMed]

213. Gharebaghi, R.; Heidary, F.; Moradi, M.; Parvizi, M. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen. Arch. Acad. Emerg. Med. 2020, 8, e40. [CrossRef] [PubMed]

214. Gendrot, M.; Duflot, I.; Boxberger, M.; Delandre, O.; Jardot, P.; Le Bideau, M.; Andreani, J.; Fonta, I.; Mosnier, J.; Rolland, C.; et al. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In Vitro inhibition of SARS-CoV-2 replication by mefloquine-artsunate. Int. J. Infect. Dis. 2020, 99, 437–440. [CrossRef] [PubMed]

215. El Ouarradi, A.; Abdeladim, S.; Oualim, S.; Filali, R.A.; Bensahi, I.; Elharass, M.; Hafid, S.; Tazi, H.; Naitlhou, A.; Bouaiti, E.A.; et al. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability. J. Saudi Heart Assoc. 2020, 32, 350–357. [CrossRef] [PubMed]

216. Shamshirian, A.; Hessami, A.; Heydari, K.; Navaei, R.A.; Ebrahimzadeh, M.A.; Yip, G.W.; Ghasemian, R.; Sedaghat, M.; Baradaran, H.; Yazdi, S.M.; et al. The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis. Ann. Acad. Med. Singap. 2020, 49, 789–800. [CrossRef] [PubMed]

217. Martín Giménez, V.M.; Prado, N.; Diez, E.; Manucha, W.; Reiter, R.J. New proposal involving nanoformulated melatonin targeted to the mitochondria as a potential COVID-19 treatment. Nanomedicine 2020. [CrossRef]

218. Cardinali, D.P.; Brown, G.M.; Pandi-Perumal, S.R. Can Melatonin Be a Potential “Silver Bullet” in Treating COVID-19 Patients? Diseases 2020, 8, 44. [CrossRef]

219. Kleszczynski, K.; Slominski, A.T.; Steinbrink, K.; Reiter, R.J. Clinical Trials for Use of Melatonin to Fight against COVID-19 are Urgently Needed. Nutrients 2020, 12, 2561. [CrossRef]

220. Öztürk, G.; Akbulut, K.G.; Güney, Ş. Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly? Turk. J. Med. Sci. 2020, 50, 1504–1512. [CrossRef]

221. Romero, A.; Ramos, E.; López-Muñoz, F.; Gil-Martin, E.; Escames, G.; Reiter, R.J. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin? Cell. Mol. Neurobiol. 2020, 1–12. [CrossRef] [PubMed]